This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.
Methods used to judge relevance and validity, and for extracting data
Not stated.
Number of primary studies included
The effectiveness evidence on beta-blockers was derived from one primary study.
Methods of combining primary studies
Not relevant.
Investigation of differences between primary studies
Results of the review
The overall and event-free survival in patients receiving beta-blockers was significantly higher than in patients receiving placebo (the data were not reported).
The one-year mortality was 14% in the placebo group and 3% in the intervention group. The number-needed-to-treat (NNT) to prevent one death was 9.
The one-year cardiovascular complication rate was 22% in the placebo group and 8% in the intervention group. The NNT to prevent one cardiovascular complication was 7.
Methods used to derive estimates of effectiveness
The authors made a crucial assumption about the success of the guidelines.
Estimates of effectiveness and key assumptions
It was assumed that the guidelines were successful in 50% of the patients who appeared to be ideal candidates for betablocker therapy.
Measure of benefits used in the economic analysis
The summary benefit measure was the lives saved per year in comparison with no guidelines. This was obtained by combining data derived from the single study, treatment efficacy from the published study, and guideline success based on authors' assumptions. This combination process also led to other intermediate measures, which will also be reported.
Direct costs
Discounting was not relevant since the costs were estimated during a one-year timeframe. The unit costs and the quantities were not presented separately. Administrative and medical services were included in the economic evaluation. Medical services comprised drugs (generic oral and intravenous atenolol) and telemetric monitoring. Administrative expenses comprised the following: the costs to support 10% of the annual salary of the physician who served as the clinical champion during the programme's first year, and 5% during subsequent years; the costs to support 20% of the salary of the surgical case manager each year; the computer programming costs; and
